Cureline Group’s Full Range of Research Services Now Available Through Scientist.com
25.7.2023 14:55:00 EEST | Business Wire | Press release
Cureline Group, an industry pioneer in precision and translational medicine, today announced its plans to showcase its full spectrum of research products and services on Scientist.com, the premier preclinical research marketplace for the biopharma sector. Biopharma researchers utilizing Scientist.com can now quickly and economically access essential services such as biobanking (including collection, processing, storage and retrieval of biological samples), human sample validation (including biomarker identification and verification), preclinical animal services and preclinical project management (protocol design, study execution and data analysis), histopathology, digital pathology and other lab services that are critical to accelerating drug discovery and development.
“We are excited to continue our longstanding partnership with Scientist.com, which has helped us connect with many biopharma researchers at top pharma and biotech companies,” stated Dr. Olga Potapova, Founder and CEO of the Cureline Group. “With our 20 years of translational CRO experience, we want to make it easy for any industry or academic scientist to access the many innovative tools and technologies and regulatory expertise that we’ve brought together under one roof.”
The Cureline Group, comprised of an array of companies including Cureline, Inc., Cureline BioPathology (CBP), Cureline Molecular Services (CMS), Cureline Baltic UAB, DolceRx Baltika UAB and the newly formed Memel Biotech, offers an extensive portfolio of ISO-certified, CAP-compliant preclinical research and biomarker/companion diagnostics services. Clinical expertise will be delivered by the recent strategic partnership of palleos healthcare (Germany) and Cureline. Offering clients a full-service approach can help reduce complexity and save time.
“The Cureline Group has evolved into a one-stop shop for high-quality research services in the preclinical research and biomarker/companion diagnostic spaces,” stated Kevin Lustig, PhD, Founder and CEO at Scientist.com. "We are delighted to feature their services on Scientist.com’s fast-growing, AI-powered marketplace."
About Cureline, Inc., and the Cureline Group of companies:
As a global leader in commercial biobanking and translational research services celebrating 20 years in business in 2023, we have completed over 5,000 projects for 850 clients. Cureline, Inc., (USA) together with other Cureline Group companies, is a global precision and translational medicine contract research organization (CRO) providing biobanking and HBS services in the preclinical phase and companion diagnostics development for clinical trials to the biopharmaceutical industry. Cureline Group management are experts in global regulatory affairs, custom protocol biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2021, UAB Cureline Baltic (Lithuania) is servicing our clients' needs in animal toxicology and preclinical efficacy studies in small animals with a focus on metastatic cancer, immunology and microbiota models. Starting in 2024, Memel Biotech UAB (Lithuania) will be providing GMP CDMO service for the ATMP clinical research community.
Visit http://www.cureline.com/ to learn more.
About Scientist.com
Scientist.com's mission is to empower and connect scientists worldwide. The company's AI-powered research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.
Visit Scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
About palleos healthcare GmbH
palleos healthcare is a full-service CRO with 50 highly experienced employees covering Phase I – IV drug and medical device clinical research services in central Europe. More than 10,000 patients at 300 sites were treated in various trials and indications with the results published in highly ranked journals. palleos healthcare also offers drug development consulting services for biotech and medtech companies, streamlining their early and pre-clinical development decisive milestones, allowing earlier and more efficient exit and reinvestment. As a certified partner with best-in-class players in the digital life science field (Veeva, Medidata, etc.), palleos healthcare offers cloud-based services for data management and decentralized clinical trials.
Visit www.palleos.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230725851885/en/
Contact information
Media Contact:
Olga Potapova, CEO, The Cureline Group
+1 415-468-6400 ext. 221
olga-potapova@cureline.com
Sean Preci, Sr. Director, Marketing & Content, Scientist.com
+1 858 771-3813 ext. 187
marketing@scientist.com
Heiko Bergmann, VP Sales & Strategy, palleos healthcare GmbH
+49 611 950 190 0 ext. 50
heiko.bergmann@palleos.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Only AI Crypto Lead Prioritization Solution Built With Law Enforcement, for Law Enforcement: Elliptic Launches Pulse24.9.2026 16:15:00 EEST | Press release
Elliptic, the global leader in on-chain risk, today launched Pulse. Pulse puts crypto lead prioritization directly in the hands of every frontline law enforcement and government officer. Crypto now touches every part of law enforcement, from the patrol officer on the street to the detective assigned to investigate the case. Pulse gives each of them a quick, accurate financial summary and a starting point: whether that's a crypto address on a suspect's phone, in a scam ATM victim's receipt, uncovered during a vehicle or pocket search, or found at the scene of an overdose, an arrest, or a seizure. An officer can input anything that looks like a wallet address or transaction hash. Pulse identifies it, reasons over the result, and returns a summary in plain language, enough for the officer to decide on the spot whether the case needs escalation. If a case needs further investigation, one click sends the full analysis forward, not just the evidence. The criminal investigations division gets
SymphonyAI Introduces Symphony Risk Intelligence, an Agent-native Platform That Unlocks Always-on Compliance™ — the Catalyst for Transforming the Financial Crime Operating Model24.9.2026 16:04:00 EEST | Press release
SymphonyAI today introduced Symphony Risk Intelligence (SRI), an enterprise-grade, agent-native platform built to unlock Always-on Compliance™. This is a critical shift from periodic to continuous risk and compliance management, in which institutions continuously reassess risk and adapt controls as regulations, threats and business activity change, rather than waiting for the next scheduled review. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924914614/en/ Current approaches have reached their structural limits. The FinCrime Frontier 2026–27 Report, released recently by SymphonyAI and AML Intelligence, finds just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, and 76.3% still review alerts manually or with only partial automation — barely changed year over year. Yet standing still isn't an option: the regulatory climate is at a major inflection point across ev
Just 4.7% of Financial Institutions Continuously Update Their Compliance Monitoring and Controls as Risk Changes, New Research Finds24.9.2026 16:04:00 EEST | Press release
SymphonyAI, a global leader in vertical AI product platforms, and AML Intelligence, the leading source of news and insight for the financial crime compliance community, today released the FinCrime Frontier 2026–27 Report, finding that most financial institutions still rely on periodic review cycles to manage financial crime risk, even as the threats and regulations they are meant to track continue to evolve dynamically. Based on the perspectives of more than 200 financial crime and compliance leaders, including senior leaders from major global financial institutions, the research finds that just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, while 56.8% have not adopted always-on compliance monitoring at all, are only exploring it, or remain at an early, pilot-stage level. The finding points to a structural gap: financial crime typologies, payment ecosystems and regulatory expectations are evolving continuously, while most c
Boomi Appoints Mike Hickman as Chief Financial Officer24.9.2026 16:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced the appointment of Mike Hickman as Chief Financial Officer. Hickman will lead Boomi's global finance and accounting organization, spanning financial planning and analysis, accounting, treasury, tax, and financial reporting. He reports to Boomi Chairman and Chief Executive Officer Steve Lucas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924761566/en/ Boomi Appoints Mike Hickman as Chief Financial Officer Hickman brings three decades of senior finance leadership in high-growth SaaS and technology companies, with experience across the full corporate lifecycle: scaling through IPO, executing a take-private, and integrating large acquisitions. He joins from Proofpoint, where he spent seven and a half years, most recently as Senior Vice President of Finance, helping guide the company through its $12.3 billion take-private and the $1.8 billion acquisition of Hornetsec
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 15:40:00 EEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom